Argenx SE: Specialist in Autoimmune Diseases Grows by 63% with Vyvgart
Reading Time: 2 minutes
Argenx researches and develops antibody therapies for patients with severe autoimmune diseases. Vyvgart, its main drug, blocks the FcRn receptor and is used to treat various neurological and rheumatological conditions. The FDA approval from May 2026 expands the addressable market for Vyvgart to all adult patients with generalized myasthenia gravis (gMG). Q1 shows impressive growth of 63%. Recent study successes and the expansion of approvals to additional indications ensure a stable cash flow that enables further investments in the pipeline...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
